Century Therapeutics, Inc. (IPSC) community

IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30

$1.63−0.11 (-6.32%)

Close on Nov 12, 2026Market cap $295.15MP/E –Yield –

Community

Notes and questions about Century Therapeutics from other investors

No posts about IPSC yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Century Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPSC.

Compare: IPSC vs AUTL · IPSC vs KYMR · IPSC vs MESO · IPSC vs ADAPY · IPSC vs FDMT

Revenue growth1556.8% · median 133.8%

Operating margin-97.2% · median -239.2%

Net margin-90.5% · median -260.8%

Company	Revenue	Growth
AUTL	$137.43M	+168.8%
IPSC	$109.16M	+1556.8%
KYMR	$102.24M	+133.8%
FDMT	$96.06M	+79952.5%
ADAPY	$65.09M	-54.0%
MESO	$7.50M	-26.5%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 78
Held by institutions: 87.3%
Auditor: Ernst & Young LLP
SEC CIK: 1850119

Advertisement
300 × 250

See a number that looks wrong?